Thiazolidinediones and fracture risk in patients with Type 2 diabetes (Q37889370)

24 August 2017

1 reference

title

Thiazolidinediones and fracture risk in patients with Type 2 diabetes (English)

1 reference

24 August 2017

0 references

0 references

1 reference

D J Betteridge

1

1 reference

24 August 2017

1 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

28

1 reference

24 August 2017

7

1 reference

24 August 2017

759-771

1 reference

Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Pioglitazone and mechanisms of CV protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinedione use and the risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinediones and fractures in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinediones and fractures: evidence from translating research into action for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Osteoporosis among patients with type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Epidemiology of fractures in 15,000 adults: the influence of age and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Fracture risk in type 2 diabetes: update of a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

A cohort study of thiazolidinediones and fractures in older adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Effect of selective serotonin reuptake inhibitors on the risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Use of proton pump inhibitors and risk of osteoporosis-related fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Long-term use of oral anticoagulants and the risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2010.03187.X

10.1111/J.1464-5491.2010.03187.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21672000